2025 - Cancer Currents Blog
-
Researchers have developed a form of cancer treatment that uses fat cells engineered to aggressively consume nutrients like glucose. When implanted in mice, the engineered cells appeared to outcompete tumors for nutrients, shrinking tumors.
-
FDA has approved zenocutuzumab (Bizengri) to treat people with pancreatic or non-small cell lung cancer whose tumors have a rare genetic alteration called an NRG1 fusion. The approval is based on a clinical trial in which the drug shrank tumors in a third of patients.
-
Results from a large NCI-funded clinical trial show that a comprehensive program that integrates intensive counseling and cessation medications may be a particularly effective way to help smokers being screened for lung cancer quit.
-
For men with metastatic castration-resistant prostate cancer, initial treatment with enzalutamide (Xtandi) combined with talazoparib (Talzenna) may help them live longer than getting enzalutamide alone, according to updated results from a large clinical trial.
-
Results from two clinical trials show that combining a procedure called TACE with an immunotherapy drug and angiogenesis inhibitor improves how long people with intermediate-stage liver cancer live without their disease returning or getting worse.
-
Certain inherited genetic changes are likely involved in the development of some cancers in children, a new study shows. The changes, called structural variants, were linked with a small percentage of children with neuroblastoma, Ewing sarcoma, and osteosarcoma.